<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Dement Neuropsychol</journal-id><journal-id journal-id-type="iso-abbrev">Dement Neuropsychol</journal-id><journal-id journal-id-type="publisher-id">dn</journal-id><journal-title-group><journal-title>Dementia &#x00026; Neuropsychologia</journal-title></journal-title-group><issn pub-type="ppub">1980-5764</issn><publisher><publisher-name>Associa&#x000e7;&#x000e3;o de Neurologia Cognitiva e do
Comportamento</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5710681</article-id><article-id pub-id-type="doi">10.1590/1980-57642016dn11-020005</article-id><article-categories><subj-group subj-group-type="heading"><subject>Views &#x00026; Reviews</subject></subj-group></article-categories><title-group><article-title>Utility of the Neuropsychiatric Inventory Questionnaire (NPI-Q) in
the assessment of a sample of patients with Alzheimer's disease in
Chile</article-title><trans-title-group xml:lang="pt"><trans-title>UTILIDADE DO QUESTION&#x000c1;RIO DE INVENT&#x000c1;RIO
NEUROPSIQUI&#x000c1;TRICO (NPI-Q) NA AVALIA&#x000c7;&#x000c3;O DE UMA AMOSTRA
DE PACIENTES COM DOEN&#x000c7;A DE ALZHEIMER NO CHILE</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name><surname>Musa</surname><given-names>Gada</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Henr&#x000ed;quez</surname><given-names>Fernando</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Mu&#x000f1;oz-Neira</surname><given-names>Carlos</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Delgado</surname><given-names>Carolina</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Lillo</surname><given-names>Patricia</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Slachevsky</surname><given-names>Andrea</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="corresp" rid="c1"/></contrib></contrib-group><aff id="aff1">
<label>1</label> Unidad de Neurolog&#x000ed;a Cognitiva y Demencias, Hospital del
Salvador, Providencia, Santiago, Chile</aff><aff id="aff2">
<label>2</label> Centro de Salud y Rehabilitaci&#x000f3;n Capredena, La Florida,
Santiago, Chile</aff><aff id="aff3">
<label>3</label> Departamento de Neurolog&#x000ed;a y Neurocirug&#x000ed;a, Hospital
Cl&#x000ed;nico Universidad de Chile</aff><aff id="aff4">
<label>4</label> Centro de Investigaci&#x000f3;n Avanzada en Educaci&#x000f3;n.
Universidad de Chile</aff><aff id="aff5">
<label>5</label> Departamento de Fisiopatolog&#x000ed;a, ICBM y Departamento de
Neurociencia Oriente, Facultad de Medicina, Universidad de Chile, Providencia,
Santiago, Chile</aff><aff id="aff6">
<label>6</label> Centro de Gerociencias, Salud Mental y Metabolismo, Providencia,
Santiago, Chile</aff><aff id="aff7">
<label>7</label> Servicio de Neurolog&#x000ed;a, Cl&#x000ed;nica Alemana</aff><aff id="aff8">
<label>8</label> Universidad de los Andes, Santiago, Chile</aff><aff id="aff9">
<label>9</label> Departamento de Neurolog&#x000ed;a Sur, Facultad de Medicina,
Universidad de Chile</aff><author-notes><corresp id="c1"><bold>Andrea Slachevsky</bold>. Av. Salvador 486 &#x02013; Facultad de Medicina Oriente
&#x02013; Universidad de Chile. E-mail: <email>aslachevsky@me.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Apr-Jun</season><year>2017</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Apr-Jun</season><year>2017</year></pub-date><volume>11</volume><issue>2</issue><fpage>129</fpage><lpage>136</lpage><history><date date-type="received"><day>16</day><month>2</month><year>2017</year></date><date date-type="accepted"><day>13</day><month>4</month><year>2017</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><p>The Neuropsychiatric Inventory Questionnaire (NPI-Q) is an informant-based
instrument that measures the presence and severity of 12 Neuropsychiatric
Symptoms (NPS) in patients with dementia, as well as informant distress.</p><sec><title>Objective</title><p>To measure the psychometric properties of the NPI-Q and the prevalence of NPS
in patients with Alzheimer's disease (AD) in Chile.</p></sec><sec><title>Methods</title><p>53 patients with AD were assessed. Subjects were divided into two different
groups: mild AD (n=26) and moderate AD (n=27). Convergent validity was
estimated by correlating the outcomes of the NPI-Q with Neuropsychiatric
Inventory (NPI) scores and with a global cognitive efficiency test
(Addenbrooke's Cognitive Examination - Revised - ACE-R). Reliability of the
NPI-Q was analysed by calculating its internal consistency. Prevalence of
NPS was estimated with both the NPI and NPI-Q.</p></sec><sec><title>Results</title><p>Positive and significant correlations were observed between the NPI-Q, the
NPI, and the ACE-R (r=0.730; p&#x0003c;0.01 and 0.315; p&#x0003c;0.05 respectively).
The instrument displayed an adequate level of reliability (Cronbach's
alpha=0.783). The most prevalent NPS were apathy/indifference (62.3%) and
dysphoria/depression (58.5%).</p></sec><sec><title>Conclusion</title><p>The NPI-Q exhibited acceptable validity and reliability indicators for
patients with AD in Chile, indicating that it is a suitable instrument for
the routine assessment of NPS in clinical practice.</p></sec></abstract><trans-abstract xml:lang="pt"><p>O Question&#x000e1;rio de Invent&#x000e1;rio Neuropsiqui&#x000e1;trico (NPI-Q)
&#x000e9; um instrumento baseado em informantes que mede a presen&#x000e7;a e a
gravidade de 12 Sintomas Neuropsiqui&#x000e1;tricos (NPS) em pacientes com
dem&#x000ea;ncia, bem como o sofrimento do informante.</p><sec><title>Objetivo</title><p>Avaliar as propriedades psicom&#x000e9;tricas do NPI-Q e a preval&#x000ea;ncia
de NPS em pacientes com doen&#x000e7;a de Alzheimer (DA).</p></sec><sec><title>M&#x000e9;todos</title><p>Foram avaliados 53 pacientes com DA. Eles foram divididos em dois grupos
diferentes: AD leve (n=26) e AD moderado (n=27). A validade convergente foi
estimada correlacionando os resultados do NPI-Q com os escores do
Invent&#x000e1;rio Neuropsiqui&#x000e1;trico (NPI) e um teste de
efici&#x000ea;ncia cognitiva global (Addenbrooke's Cognitive Examination -
Revised - ACE-R). A confiabilidade do NPI-Q foi analisada pelo
c&#x000e1;lculo da sua consist&#x000ea;ncia interna. A preval&#x000ea;ncia de
NPS foi estimada com NPI e NPI-Q.</p></sec><sec><title>Resultados</title><p>Foram observadas correla&#x000e7;&#x000f5;es positivas e significativas entre
NPI-Q, NPI e ACE-R (r=0,730; p&#x0003c;0,01 e 0&#x0003e;315; p&#x0003c;0&#x0003e;05). O
instrumento apresentou um n&#x000ed;vel adequado de confiabilidade (alfa de
Cronbach=0J83). Os NPS mais prevalentes foram apatia/indiferen&#x000e7;a
(62,3%) e disforia/depress&#x000e3;o (58,5%).</p></sec><sec><title>Conclus&#x000e3;o</title><p>O NPI-Q apresenta indicadores de validade e confiabilidade aceit&#x000e1;veis
em pacientes com DA, o que indica que &#x000e9; um instrumento adequado para
a avalia&#x000e7;&#x000e3;o rotineira de NPS na pr&#x000e1;tica
cl&#x000ed;nica.</p></sec></trans-abstract><kwd-group><kwd>dementia</kwd><kwd>assessment</kwd><kwd>neuropsychiatric inventory</kwd><kwd>Alzheimer's disease</kwd><kwd>prevalence</kwd><kwd>neuropsychiatric symptoms</kwd></kwd-group><kwd-group xml:lang="pt"><kwd>dem&#x000ea;ncia</kwd><kwd>avalia&#x000e7;&#x000e3;o</kwd><kwd>invent&#x000e1;rio neuropsiqui&#x000e1;trico</kwd><kwd>doen&#x000e7;a de Alzheimer</kwd><kwd>preval&#x000ea;ncia</kwd><kwd>sintomas neuropsiqui&#x000e1;tricos</kwd></kwd-group><funding-group><award-group><funding-source>Conicyt</funding-source><award-id>1140423</award-id><award-id>1100975</award-id><award-id>1160940</award-id><award-id>15150012</award-id></award-group><funding-statement><bold>Funding.</bold> This study was funded through Conicyt/Fondecyt Regular
Projects N&#x000b0;1140423, 1100975 &#x00026; 1160940 CONICYT/FONDAP/15150012, Fondos
Basales para Centros de Excelencia PIA-CONICYT Project BF0003.
</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>Life expectancy in Latin America has rapidly increased over recent years. Chile has
one of the highest rates of population ageing within the zone, with 11.4% growth in
individuals aged 60 or older.<sup><xref rid="r1" ref-type="bibr">1</xref>,<xref rid="r2" ref-type="bibr">2</xref></sup> Dementia is the most frequent mental
disorder in this population and cases worldwide are expected to increase 68% by
2050. The estimated number of people with dementia in Chile was 150,293 in 2010,
181,761 in 2015 and is set to reach 533,188 in 2050.<sup><xref rid="r3" ref-type="bibr">3</xref></sup> Additionally, the dependency rate associated with
dementia is estimated to be roughly 37.8% higher than that of the general
population. Concerning different types of dementia and their frequency, Alzheimer's
disease (AD) is the most prevalent subtype, accounting for approximately 70% of all
cases. The second most common cause of dementia is vascular dementia, accounting for
10-20% of cases, followed by Frontotemporal and Lewy Body dementias.<sup><xref rid="r4" ref-type="bibr">4</xref>,<xref rid="r5" ref-type="bibr">5</xref></sup></p><p>Regardless of the type of dementia, besides its characteristic progressive cognitive
and functional impairment, this syndrome is usually accompanied by behavioral
disorders, also referred to as Neuropsychiatric Symptoms (NPS), which can be defined
as non-cognitive/behavioral symptoms that include mood, perception, and behavior
alterations.<sup><xref rid="r6" ref-type="bibr">6</xref></sup> In terms of
the likely emergence of NPS, several studies have indicated that more than 80% of
patients with dementia experience at least one NPS,<sup><xref rid="r6" ref-type="bibr">6</xref></sup> with increasing severity as the disease
progresses.<sup><xref rid="r7" ref-type="bibr">7</xref>,<xref rid="r8" ref-type="bibr">8</xref></sup> Similarly, data from the Cache
County Study showed a 97% prevalence of at least one NPS with the most frequent
symptoms being depression (77%), apathy (71%) and anxiety (62%).<sup><xref rid="r9" ref-type="bibr">9</xref></sup></p><p>There are different types of NPS, probably due to the various etiological mechanisms
that underpin each type of dementia.<sup><xref rid="r8" ref-type="bibr">8</xref>-<xref rid="r10" ref-type="bibr">10</xref></sup> Exploring the
likely presence of NPS in patients with dementia is critical for an appropriate
differential diagnosis. Their assessment is important given the relationship
existing between the presence of NPS and decline in quality of life, increased
institutionalization, and rise in patient mortality.<sup><xref rid="r11" ref-type="bibr">11</xref></sup> These issues result in a high level of caregiver
burden and greater economic costs because of the frequent use of
medication.<sup><xref rid="r9" ref-type="bibr">9</xref>-<xref rid="r12" ref-type="bibr">12</xref></sup></p><p>Complementary, NPS assessment is relevant in dementia care, considering that it might
provide an insight into the management of the behavioural disorders emerging from
the difficulties of each case, given that they become more frequent as the disease
progresses.</p><p>In this context, appropriate assessment of NPS becomes extremely important for the
differential diagnosis of dementia, its related clinical practice, and the
assessment of patients' behavioural response to treatments.</p><p>One of the most common scales for assessing the presence and severity of NPS in
dementia is the Neuropsychiatric Inventory (NPI),<sup><xref rid="r13" ref-type="bibr">13</xref></sup> a carer-based tool that assesses the possible
presence of 12 symptoms in dementia cases, including delusions, hallucinations,
agitation/aggression, dysphoria/depression, anxiety, euphoria/elation,
apathy/indifference, disinhibition, irritability/lability, aberrant motor behaviors,
night-time behavioral disturbances and appetite/eating disturbances. This scale is
very useful and widely employed in research; however, its administration is
time-consuming for health professionals, discouraging its inclusion in everyday
clinical practice. In order to tackle this drawback, Kaufer et al.<sup><xref rid="r14" ref-type="bibr">14</xref></sup> developed a shorter version of the
instrument: the Neuropsychiatric Inventory Questionnaire (NPI-Q), another
informant-based instrument that is easier to administer in both clinical and
research settings. This questionnaire assesses the possible presence of the same 12
NPS included in the NPI and also provides an index to grade the corresponding
severity of each symptom and the respective distress it causes on the caregiver. The
Spanish version of the NPI-Q developed by Boada et al. has shown appropriate
validity and reliability in Spain.<sup><xref rid="r15" ref-type="bibr">15</xref></sup> Nevertheless, in Latin America it has been validated only for
Brazil<sup><xref rid="r16" ref-type="bibr">16</xref></sup> and
Mexico<sup><xref rid="r17" ref-type="bibr">17</xref></sup> so far, while
validation in other Latin American countries, including Chile, remains pending.</p><p>The main objective of this study was to assess the psychometric properties of the
NPI-Q in Chile. The secondary objective was to compare the prevalence and severity
of NPS in a Chilean sample comprising patients with AD.</p></sec><sec sec-type="methods"><title>METHODS</title><p><bold>Participants.</bold> A convenience sample of 53 patients with mild and moderate
AD and their respective caregivers was included in this study. AD diagnoses were
established by a neurologist based both on the Clinical Dementia Rating Scale
(CDR)<sup><xref rid="r18" ref-type="bibr">18</xref></sup> and on the
National Institute of Neurological and Communicative Disorders and Strokes and the
Alzheimer's Disease and Related Disorders Association - NINCDS-ADRDA -
criteria.<sup><xref rid="r19" ref-type="bibr">19</xref></sup> The
subdivision of the sample into two different groups was done according to CDR Global
Score: mild AD (n=26; CDR=1) and moderate AD (n=27; CDR&#x0003e;2). The inclusion
criteria considered participants of both sexes, over 65 years old, Spanish speakers,
and with at least 4 years of education. Patients were recruited from the Cognitive
Neurology and Dementia Unit of the Neurology Service at the Hospital del Salvador
and from the Neurology and Neurosurgery Service at the Hospital Cl&#x000ed;nico
Universidad de Chile (HCUCH) in Santiago, Chile. Each participant was asked to sign
an informed consent form, revised by the Ethics Committee of the West Metropolitan
Health Service and that of the HCUCH in Santiago, Chile. All the subjects with AD
underwent a full neurological examination, a neuropsychological assessment, and
neuroimaging procedures (Structural Magnetic Resonance) to confirm their diagnoses.
The exclusion criteria were severe sensory deficits (hearing and vision), a history
of strokes, and major psychiatric disorders.</p><sec><title>Instruments</title><p><italic>Neuropsychiatric Inventory (NPI).</italic> The NPI<sup><xref rid="r13" ref-type="bibr">13</xref></sup> is a retrospective (1 month)
caregiver/informant-based interview covering 12 NPS, including delusions,
hallucinations, agitation/aggression, dysphoria/depression, anxiety,
euphoria/elation, apathy/indifference, disinhibition, irritability/lability,
aberrant motor behaviors, night-time behavioral disturbances and appetite/eating
disturbances. The scripted NPI interview includes a compound screening question
for each symptom domain, followed by a list of questions about domain specific
behaviors administered when a positive response to a screening question is
elicited. Neuropsychiatric symptoms are rated by the caregiver within a domain
in terms of both frequency (1=rarely, less than once per week; 2=sometimes,
about once per week; 3=often, several times per week; and 4=very often, once or
more per day) and severity (1=mild; 2=moderate; 3=severe), thus yielding a
composite symptom domain score (frequency &#x000d7; severity) ranging from 0
(absence of behavioral symptoms) to 144 points (maximum severity of behavioral
symptoms). Frequency and severity rating scales have anchor points to enhance
the reliability of caregiver responses. Caregiver distress is rated for each
positive neuropsychiatric symptom domain on a scale anchored by scores from 0 to
5 points (0=no distress; 1=minimal distress; 2=mild distress; 3=moderate
distress; 4=severe distress; and 5=very severe distress). The NPI is
administered as a structured interview taking roughly 20 minutes.</p><p><italic>Neuropsychiatric Inventory Questionnaire (NPI-Q).</italic> The
NPI-Q<sup><xref rid="r14" ref-type="bibr">14</xref></sup> is a
caregiver-based questionnaire in which the carer indicates the presence or
absence of NPS in the patient during the last few weeks. It can be completed in
5 to 10 minutes and assesses the same 12 behavioral symptoms as the NPI;
however, unlike the NPI, the NPI-Q only considers the severity of NPS and
caregiver distress. The severity scale has scores ranging from 1 to 3 points
(1=mild; 2=moderate; and 3=severe) and the scale for assessing caregiver
distress has scores ranging from 0 to 5 points (0=no distress; 1=minimal
distress; 2=mild distress; 3=moderate distress; 4=severe distress; and 5=extreme
distress). The NPI-Q has proven valid and has acceptable levels of internal
consistency.<sup><xref rid="r14" ref-type="bibr">14</xref></sup></p><p><bold>Other instruments.</bold> In addition, the Addenbrooke's Cognitive
Examination - Revised - Chilean Version - (ACE-R-Ch)<sup><xref rid="r20" ref-type="bibr">20</xref></sup> and the CDR<sup><xref rid="r18" ref-type="bibr">18</xref></sup> were administered as a measure of global
cognitive efficiency and dementia severity respectively.</p><p><bold>Procedure and data analysis.</bold> Firstly, the NPI was administered to
the primary caregiver of each patient with AD included in this study.
Subsequently, the NPI-Q was filled in by the same carer two weeks later. This
gap of two weeks between the administration of the NPI and the NPI-Q was due to
logistical reasons. It was assumed that this interval had no influence on
patients' behavioural changes, as all the participants in this study had stable
clinical pictures during the preceding 6 months of assessment.</p><p>The statistical analysis was performed with the IBM SPSS 22 package.<sup><xref rid="r21" ref-type="bibr">21</xref></sup> Descriptive demographic data
and clinical profiles were obtained for the sample. A comparative analysis was
conducted to estimate the prevalence of NPS in this sample of AD patients
according to the NPI and the NPI-Q. The Chi-squared test was employed to compare
and assess whether there were significant differences between the scales in
terms of the frequency/percentage of each symptom. The Mann-Whitney U test for
independent samples was used to compare the two groups (CDR=1 and 2) and detect
significant differences in the means of each NPS.</p><p>In order to estimate the convergent validity of the instrument, a correlation
analysis was performed according to the distribution of each variable (Pearson's
r or Spearman's rho where appropriate) among the NPI (total score, severity,
distress, and by domain), the NPI-Q (total score, severity, distress, and by
domain), and the ACE-R-Ch. In order to determine the reliability of the NPI-Q,
its internal consistency was estimated with Cronbach's alpha.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p><bold>Demographic data and clinical profiles.</bold>
<xref ref-type="table" rid="t1">Table 1</xref> summarizes the demographic and
clinical data of the total sample (n=53). The sample was divided, according to CDR
scores, into CDR=1 (n=26) and CDR=2 (n=27). Concerning clinical profiles,
significant differences were found between the groups (p&#x0003c;0.05) in global
cognitive efficiency measures (ACE-R-Ch), Total NPI, Total NPI-Q, and NPI-Q
Distress.</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Clinical and demographic data.</p></caption><table frame="hsides" rules="rows"><colgroup span="1"><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" style="background-color:#D1D2D4" rowspan="1" colspan="1">Variable</th><th align="center" style="background-color:#D1D2D4" rowspan="1" colspan="1">All (n=53)</th><th align="center" style="background-color:#D1D2D4" rowspan="1" colspan="1">CDR=1 (n=26)</th><th align="center" style="background-color:#D1D2D4" rowspan="1" colspan="1">CDR=2 (n=27)</th><th align="center" style="background-color:#D1D2D4" rowspan="1" colspan="1">Caregivers</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="center" rowspan="1" colspan="1">73.8&#x000b1;6.87</td><td align="center" rowspan="1" colspan="1">74.4&#x000b1;6.5</td><td align="center" rowspan="1" colspan="1">73.3&#x000b1;6.3</td><td align="center" rowspan="1" colspan="1">63.66&#x000b1;12.66</td></tr><tr><td align="left" rowspan="1" colspan="1">Education (years)</td><td align="center" rowspan="1" colspan="1">11.5&#x000b1;4.82</td><td align="center" rowspan="1" colspan="1">12.2&#x000b1;4.6</td><td align="center" rowspan="1" colspan="1">10.9&#x000b1;4.9</td><td align="center" rowspan="1" colspan="1">12.32&#x000b1;5.05</td></tr><tr><td align="left" rowspan="1" colspan="1">Total ACE-R score<xref ref-type="table-fn" rid="TFN2">*</xref></td><td align="center" rowspan="1" colspan="1">61.02&#x000b1;16.18</td><td align="center" rowspan="1" colspan="1">70.2&#x000b1;12.5</td><td align="center" rowspan="1" colspan="1">52.2&#x000b1;14.4</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Total NPI score<xref ref-type="table-fn" rid="TFN2">*</xref></td><td align="center" rowspan="1" colspan="1">17.58&#x000b1;20.61</td><td align="center" rowspan="1" colspan="1">11.6&#x000b1;12.8</td><td align="center" rowspan="1" colspan="1">23.3&#x000b1;24.9</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">NPI - Distress score</td><td align="center" rowspan="1" colspan="1">8.21&#x000b1;8.63</td><td align="center" rowspan="1" colspan="1">5.9&#x000b1;7.2</td><td align="center" rowspan="1" colspan="1">10.4&#x000b1;9.4</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Total NPI-Q score<xref ref-type="table-fn" rid="TFN2">*</xref></td><td align="center" rowspan="1" colspan="1">8.64&#x000b1;6.54</td><td align="center" rowspan="1" colspan="1">6.3&#x000b1;4.8</td><td align="center" rowspan="1" colspan="1">10.5&#x000b1;7.2</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">NPI-Q - Distress score<xref ref-type="table-fn" rid="TFN2">*</xref></td><td align="center" rowspan="1" colspan="1">11.09&#x000b1;9.87</td><td align="center" rowspan="1" colspan="1">7.4&#x000b1;7.9</td><td align="center" rowspan="1" colspan="1">14.1&#x000b1;10.4</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>Results expressed as Mean&#x000b1;Standard Deviation.</p></fn><fn id="TFN2"><label>*</label><p>Groups differ significantly (p&#x0003e; 0.05)</p></fn></table-wrap-foot></table-wrap><p><bold>NPI-Q.</bold> All the patients displayed at least one neuropsychiatric symptom
on both the NPI and NPI-Q scales (<xref ref-type="table" rid="t1">Table
1</xref>).</p><p>The correlation between the NPI total score (sum of the products of severity per
frequency of all domains) and the NPI-Q total score (sum of the severity scale of
all domains) was positive, high, and significant (r=0.73; p&#x0003c;0.01). Similarly, the
correlation between the scores on the NPI and NPI-Q distress scales was positive,
high, and significant (r=0.715; p&#x0003c;0.01).</p><p>Regarding the ACE-R, a negative, moderate and significant correlation index was
observed between the ACE-R-Ch and the total NPI-Q score (r=-0.315; p&#x0003c;0.01) (<xref ref-type="table" rid="t2">Table 2</xref>)</p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Inter-scale correlations among the NPI, NPI-Q, and ACE-R-Ch.</p></caption><table frame="hsides" rules="rows"><colgroup span="1"><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr><th align="left" style="background-color:#D1D2D4" rowspan="1" colspan="1">Variables</th><th align="center" style="background-color:#D1D2D4" rowspan="1" colspan="1">All (n=53)</th><th align="center" style="background-color:#D1D2D4" rowspan="1" colspan="1">CDR=1 (n=26)</th><th align="center" style="background-color:#D1D2D4" rowspan="1" colspan="1">CDR=2 (n=27)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">NPI-Q -Total/NPI - Total<sup><xref ref-type="table-fn" rid="TFN7">b</xref></sup></td><td align="center" rowspan="1" colspan="1">0.730<xref ref-type="table-fn" rid="TFN4">**</xref></td><td align="center" rowspan="1" colspan="1">0.725<xref ref-type="table-fn" rid="TFN4">**</xref></td><td align="center" rowspan="1" colspan="1">0.691<xref ref-type="table-fn" rid="TFN4">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">NPI-Q - Distress/NPI - Distress<sup><xref ref-type="table-fn" rid="TFN7">b</xref></sup></td><td align="center" rowspan="1" colspan="1">0.715<xref ref-type="table-fn" rid="TFN4">**</xref></td><td align="center" rowspan="1" colspan="1">0.671<xref ref-type="table-fn" rid="TFN4">**</xref></td><td align="center" rowspan="1" colspan="1">0.671<xref ref-type="table-fn" rid="TFN4">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">NPI-Q - Total/NPI-Q - Distress<sup><xref ref-type="table-fn" rid="TFN7">b</xref></sup></td><td align="center" rowspan="1" colspan="1">0.900<xref ref-type="table-fn" rid="TFN4">**</xref></td><td align="center" rowspan="1" colspan="1">0.818<xref ref-type="table-fn" rid="TFN4">**</xref></td><td align="center" rowspan="1" colspan="1">0.912<xref ref-type="table-fn" rid="TFN4">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">NPI - Total/NPI - Distress<sup><xref ref-type="table-fn" rid="TFN7">b</xref></sup></td><td align="center" rowspan="1" colspan="1">0.882<xref ref-type="table-fn" rid="TFN4">**</xref></td><td align="center" rowspan="1" colspan="1">0.834<xref ref-type="table-fn" rid="TFN4">**</xref></td><td align="center" rowspan="1" colspan="1">0.929<xref ref-type="table-fn" rid="TFN4">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">NPI-Q - Total/ACE-R<sup><xref ref-type="table-fn" rid="TFN6">a</xref></sup></td><td align="center" rowspan="1" colspan="1">-0.315<xref ref-type="table-fn" rid="TFN3">*</xref></td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN5">n.s.</xref></td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN5">n.s.</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">NPI - Total/ACE-R<sup><xref ref-type="table-fn" rid="TFN6">a</xref></sup></td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN5">n.s.</xref></td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN5">n.s.</xref></td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN5">n.s.</xref></td></tr></tbody></table><table-wrap-foot><fn id="TFN3"><label>*</label><p>p&#x0003c; 0.05;</p></fn><fn id="TFN4"><label>**</label><p>p&#x0003c; 0.01;</p></fn><fn id="TFN5"><label>n.s.</label><p>Non-significant.</p></fn><fn id="TFN6"><label>a</label><p>Pearson's correlation coefficient (r).</p></fn><fn id="TFN7"><label>b</label><p>Spearman's correlation coefficient (r).</p></fn></table-wrap-foot></table-wrap><p>Correlating the presence of symptoms in terms of the NPI and NPI-Q, the per-domain
correlations indicated a range of values between 0.292 and 0.708 (p&#x0003c;0.01).
According to the score on each domain, significant correlations were found
(p&#x0003c;0.05), ranging from 0.383 to 0.962, for hallucinations, dysphoria/depression,
anxiety, apathy/indifference, night-time and appetite/eating disturbances. The
distress scale showed the smallest number of symptoms that correlated with each
other. Despite this, dysphoria/depression, anxiety, apathy/indifference, and
irritability were the only NPS that showed significant values, ranging from p=0.438
to p=0.627 (p&#x0003c;0.05) (<xref ref-type="table" rid="t3">Table 3</xref>). In
addition, the instrument displayed a good level of internal consistency (Cronbach's
alpha=0.783).</p><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Inter-scale correlations between the NPI and the NPI-Q.</p></caption><table frame="hsides" rules="rows"><colgroup span="1"><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr><th align="left" style="background-color:#D1D2D4" rowspan="1" colspan="1">Domain</th><th align="center" style="background-color:#D1D2D4" rowspan="1" colspan="1">NPI-Q
Symptom/NPI</th><th align="center" style="background-color:#D1D2D4" rowspan="1" colspan="1">NPI-Q - Total/NPI -
Total</th><th align="center" style="background-color:#D1D2D4" rowspan="1" colspan="1">NPI-Q - Distress/NPI
- Distress</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Delusions<sup><xref ref-type="table-fn" rid="TFN11">a</xref></sup></td><td align="center" rowspan="1" colspan="1">0.628<xref ref-type="table-fn" rid="TFN9">**</xref></td><td align="center" rowspan="1" colspan="1">0.678</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN10">n.s.</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Hallucinations<sup><xref ref-type="table-fn" rid="TFN11">a</xref></sup></td><td align="center" rowspan="1" colspan="1">0.542<xref ref-type="table-fn" rid="TFN9">**</xref></td><td align="center" rowspan="1" colspan="1">0.962<xref ref-type="table-fn" rid="TFN8">*</xref></td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN10">n.s.</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Agitation/Aggression<sup><xref ref-type="table-fn" rid="TFN11">a</xref></sup></td><td align="center" rowspan="1" colspan="1">0.413<xref ref-type="table-fn" rid="TFN9">**</xref></td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN10">n.s.</xref></td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN10">n.s.</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Dysphoria/Depression<sup><xref ref-type="table-fn" rid="TFN12">b</xref></sup></td><td align="center" rowspan="1" colspan="1">0.653<xref ref-type="table-fn" rid="TFN9">**</xref></td><td align="center" rowspan="1" colspan="1">0.383<xref ref-type="table-fn" rid="TFN8">*</xref></td><td align="center" rowspan="1" colspan="1">0.438<xref ref-type="table-fn" rid="TFN9">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Anxiety<sup><xref ref-type="table-fn" rid="TFN12">b</xref></sup></td><td align="center" rowspan="1" colspan="1">0.673<xref ref-type="table-fn" rid="TFN9">**</xref></td><td align="center" rowspan="1" colspan="1">0.499<xref ref-type="table-fn" rid="TFN8">*</xref></td><td align="center" rowspan="1" colspan="1">0.594<xref ref-type="table-fn" rid="TFN9">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Euphoria/Elation<sup><xref ref-type="table-fn" rid="TFN12">b</xref></sup></td><td align="center" rowspan="1" colspan="1">0.292<xref ref-type="table-fn" rid="TFN8">*</xref></td><td align="center" rowspan="1" colspan="1">--</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Apathy/Indifference<sup><xref ref-type="table-fn" rid="TFN12">b</xref></sup></td><td align="center" rowspan="1" colspan="1">0.450<xref ref-type="table-fn" rid="TFN9">**</xref></td><td align="center" rowspan="1" colspan="1">0.433<xref ref-type="table-fn" rid="TFN8">*</xref></td><td align="center" rowspan="1" colspan="1">0.627<xref ref-type="table-fn" rid="TFN9">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Disinhibition<sup><xref ref-type="table-fn" rid="TFN12">b</xref></sup></td><td align="center" rowspan="1" colspan="1">0.632<xref ref-type="table-fn" rid="TFN9">**</xref></td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN10">n.s.</xref></td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN10">n.s.</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Irritability/Lability<sup><xref ref-type="table-fn" rid="TFN12">b</xref></sup></td><td align="center" rowspan="1" colspan="1">0.708<xref ref-type="table-fn" rid="TFN9">**</xref></td><td align="center" rowspan="1" colspan="1">0.419<xref ref-type="table-fn" rid="TFN8">*</xref></td><td align="center" rowspan="1" colspan="1">0.496<xref ref-type="table-fn" rid="TFN9">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Aberrant Motor Behavior<sup><xref ref-type="table-fn" rid="TFN12">b</xref></sup></td><td align="center" rowspan="1" colspan="1">0.522<xref ref-type="table-fn" rid="TFN9">**</xref></td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN10">n.s.</xref></td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN10">n.s.</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Nighttime Behavioral Disturbances<sup><xref ref-type="table-fn" rid="TFN12">b</xref></sup></td><td align="center" rowspan="1" colspan="1">0.676<xref ref-type="table-fn" rid="TFN9">**</xref></td><td align="center" rowspan="1" colspan="1">0.861<xref ref-type="table-fn" rid="TFN9">**</xref></td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN10">n.s.</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Appetite/Eating Disturbances<sup><xref ref-type="table-fn" rid="TFN12">b</xref></sup></td><td align="center" rowspan="1" colspan="1">0.580<xref ref-type="table-fn" rid="TFN9">**</xref></td><td align="center" rowspan="1" colspan="1">0.655<xref ref-type="table-fn" rid="TFN8">*</xref></td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN10">n.s.</xref></td></tr></tbody></table><table-wrap-foot><fn id="TFN8"><label>*</label><p>p&#x0003c; 0.05;</p></fn><fn id="TFN9"><label>**</label><p>p&#x0003c; 0.01;</p></fn><fn id="TFN10"><label>n.s</label><p>Non-significant.</p></fn><fn id="TFN11"><label>a</label><p>Pearson's correlation coefficient (r).</p></fn><fn id="TFN12"><label>b</label><p>Spearman's correlation coefficient (r).</p></fn></table-wrap-foot></table-wrap><p>The prevalence of the neuropsychiatric symptoms was analyzed using both scales.
According to the NPI-Q, the most frequent NPS in AD was apathy/indifference (62.3%),
followed by dysphoria/depression (58.5%) and irritability (52.8%). The least
frequent NPS in AD were hallucinations (17%) and euphoria/elation (11.3%) (<xref ref-type="fig" rid="f1">Figure 1</xref>).</p><p><fig id="f1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Comparison of the prevalence of neuropsychiatric symptoms in patients
with AD using the NPI and the NPI-Q.</p></caption><graphic xlink:href="dn-11-02-0129-g01"/></fig></p><p>A significant proportion of the NPS had non-significant differences between the NPI
and the NPI-Q. Nevertheless, euphoria/elation was the only NPS whose prevalence
differed significantly between the two scales (Chi-squared=4.5; p&#x0003e; 0.05) (<xref ref-type="fig" rid="f1">Figure 1</xref>).</p><p>The comparison of the sample according to the severity of dementia (CDR=1 and CDR=2)
revealed an increase in the prevalence of all NPS as the disease progressed, except
for night-time disturbances, whose prevalence decreased. The symptoms whose
prevalence showed the highest increase included delusions (44.2%),
agitation/aggression (36.7%), and aberrant motor behavior (28.9%) (<xref ref-type="fig" rid="f2">Figure 2</xref>). Significant differences were observed
between the two groups regarding the presence of delusions, agitation/aggression,
and aberrant motor behavior (<xref ref-type="fig" rid="f2">Figure 2</xref>).</p><p><fig id="f2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Prevalence of neuropsychiatric symptoms according to the NPI-Q in
patients with mild (CDR=1) and moderate (CDR=2) AD.</p></caption><graphic xlink:href="dn-11-02-0129-g02"/></fig></p></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>The first aim of this study was to examine the psychometric properties and utility of
the NPI-Q in a Chilean sample of patients with AD, given that one of the main
purposes of this instrument is to facilitate the routine assessment of NPS for
dementia cases in everyday clinical practice settings. The second goal of the study
was to analyze the frequency of NPS in AD in Chile and to identify any possible
differences associated with the severity of dementia.</p><p>The following section provides a detailed analysis of these results.</p><p><bold>Psychometric properties.</bold> The NPI-Q showed appropriate convergent
validity and internal reliability with respect to total and individual symptom
domain scores and caregiver distress ratings on the NPI. Both results are in
accordance with those reported in the validation of the original scale<sup><xref rid="r14" ref-type="bibr">14</xref></sup> and with those of the Spanish
version.<sup><xref rid="r15" ref-type="bibr">15</xref></sup></p><p>The NPI-Q distress scale was strongly and very significantly associated with the
severity of NPS. These results are consistent with those reported in previous
studies analyzing the impact of NPS on caregiver burden and quality of life.
Kochhann et al.<sup><xref rid="r22" ref-type="bibr">22</xref></sup> studied this
association and concluded that NPS in patients with AD are the main cause of
caregiver distress and burden, and that this association becomes stronger as the
severity of dementia increases.</p><p>The NPI-Q symptom severity scale showed a strong correlation with both the severity
scale and with the composite frequency &#x000d7; severity score (total score) from
the NPI, with the correlation index remaining stable regardless of the severity of
dementia (once the sample had been divided according to CDR). These results are also
in line with the original studies.<sup><xref rid="r14" ref-type="bibr">14</xref>,<xref rid="r15" ref-type="bibr">15</xref></sup></p><p>Thus, the present study provides sufficient evidence to assert that the NPI-Q had
acceptable psychometric properties when tested in a cohort of Chilean patients with
AD.</p><p><bold>Neuropsychiatric symptom frequency.</bold> According to prior research, over
80% of patients with dementia experience at least one NPS.<sup><xref rid="r6" ref-type="bibr">6</xref>,<xref rid="r7" ref-type="bibr">7</xref></sup> The results
of the present study showed similar indexes, as 100% of the patients included in the
sample displayed at least one neuropsychiatric symptom according to the NPI and
NPI-Q.</p><p>Based on the results obtained in this study, the most common NPS in patients with AD
in Chile was apathy/indifference, followed by dysphoria/depression and irritability.
In contrast, the least frequent symptoms were hallucinations and euphoria/elation.
Only irritability was more prevalent in comparison with the results published by
Qing-Fei et al.<sup><xref rid="r23" ref-type="bibr">23</xref></sup> These
researchers, from a meta-analysis of prior studies, concluded that the most frequent
NPS in AD were apathy/indifference, dysphoria/depression, agitation/aggression,
anxiety, night-time behavioural disturbances, and irritability, in decreasing order
of prevalence.</p><p>Our results are consistent with findings of another study conducted in Chile that
showed apathy/indifference, anxiety, and irritability to be the most prevalent
symptoms in these patients;<sup><xref rid="r24" ref-type="bibr">24</xref></sup> in
addition, the present study indicated that dysphoria/depression is one of the main
NPS observed in AD.</p><p>Comparing the prevalence of NPS according to the severity of dementia, our results
showed that only night-time disturbances decreased, whereas delusions,
agitation/aggression, and aberrant motor behavior increased as the disease
progressed. In a longitudinal study, Brodaty et al.<sup><xref rid="r25" ref-type="bibr">25</xref></sup> concluded that symptoms such as depression,
euphoria/elation, and night-time and eating disturbances did not increase
significantly in frequency, but hallucinations, agitation/aggression, aberrant motor
behavior, and apathy/indifference, among other symptoms, became more prevalent. By
contrast, Bergh and Selb&#x000e6;k,<sup><xref rid="r26" ref-type="bibr">26</xref></sup> also
in a meta-analysis, concluded that although the course of NPS is heterogeneous, most
display some increase, where aggression was the most persistent symptom.<sup><xref rid="r26" ref-type="bibr">26</xref></sup></p><p>The prevalence of NPS assessed by the two scales differed by 6.1% overall in this
study, and depending on the specific domain, tended to be higher or lower on the
NPI-Q. This result is consistent with the original validation of the NPI-Q<sup><xref rid="r14" ref-type="bibr">14</xref></sup> and its Spanish version,<sup><xref rid="r15" ref-type="bibr">15</xref></sup> which showed differences of 5% and
6.7%, respectively. These differences in prevalence between the two scales could be
explained by the fluctuations in NPS over time.</p><p>The NPI-Q is also useful because it provides an indicator for assessing global and
NPS-related caregiver distress; in fact, it has already been used in multiple
studies assessing this variable,<sup><xref rid="r27" ref-type="bibr">27</xref>-<xref rid="r29" ref-type="bibr">29</xref></sup> allowing planning of personalized
intervention strategies for caregivers.</p><p><bold>Limitations.</bold> This study was conducted in caregivers/informants with an
average educational level where the administration of the questionnaires was aided
by professionals when questions were not readily understood. This point is of
special consideration for clinical practice, particularly when involving low
socioeconomic status population groups whose understanding of the questions may be
limited. Likewise, it is advisable for the administration of the NPI-Q to be
assisted or alternatively, the instrument can be used as a brief interview, which
should facilitate and ensure faithful representation of the patient's reality.</p><p>One of the main limitations of our study is the inclusion of only AD patients.
Further studies should include other dementia and neuropsychiatric conditions to
determine the validity of NPI in other diseases. Nevertheless, previous evidence in
other countries supports the extrapolation of the NPI-Q to other forms of
dementia.</p><p>In summary, given the good psychometric properties and utility of the NPI-Q scale, it
can be concluded that the instrument is suitable for assessing NPS in dementias in
everyday clinical practice in Chile, having proven being brief, simple, valid, and
reliable.</p></sec></body><back><fn-group><fn fn-type="COI-statement"><p>Disclosure: The authors report no conflicts of interest.</p></fn><fn fn-type="con"><p><bold>Author contribution.</bold> All authors contributed to the conception and
design of the research project, analysis and interpretation of data, drafting of
the article and critical revision of intellectual content.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding.</bold> This study was funded through Conicyt/Fondecyt Regular
Projects N&#x000b0;1140423, 1100975 &#x00026; 1160940 CONICYT/FONDAP/15150012, Fondos
Basales para Centros de Excelencia PIA-CONICYT Project BF0003.</p></fn><fn fn-type="other"><p>This study was conducted at the Unidad de Neurolog&#x000ed;a Cognitiva y
Demencias, Hospital del Salvador Providencia, Santiago, Chile.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albala</surname><given-names>C</given-names></name><name><surname>Vio</surname><given-names>F</given-names></name></person-group><article-title>Epidemiological transition in Latin America: the case of
Chile</article-title><source>Public Health</source><year>1995</year><volume>109</volume><fpage>431</fpage><lpage>442</lpage><pub-id pub-id-type="pmid">8570804</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albala</surname><given-names>C</given-names></name><name><surname>Vio</surname><given-names>F</given-names></name><name><surname>Kain</surname><given-names>J</given-names></name><name><surname>Uauy</surname><given-names>R</given-names></name></person-group><article-title>Nutrition transition in Latin America: the case of
Chile</article-title><source>Nutrition Rev</source><year>2001</year><volume>59</volume><fpage>170</fpage><lpage>176</lpage><pub-id pub-id-type="pmid">11444593</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuentes</surname><given-names>P</given-names></name><name><surname>Albala</surname><given-names>C</given-names></name></person-group><article-title>An update on aging and dementia in Chile</article-title><source>Dement Neuropsychol</source><year>2014</year><volume>4</volume><fpage>317</fpage><lpage>322</lpage></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blossom</surname><given-names>S</given-names></name><name><surname>Brayne</surname><given-names>C</given-names></name></person-group><article-title>Prevalence and projections of dementia. Excellence in dementia
care: research into practice</article-title><source>Berkshire: McGraw-Hill;</source><year>2008</year><fpage>9</fpage><lpage>34</lpage></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lyketsos</surname><given-names>C</given-names></name><name><surname>Steinberg</surname><given-names>M</given-names></name><name><surname>Tschanz</surname><given-names>J</given-names></name><name><surname>Norton</surname><given-names>M</given-names></name><name><surname>Steffens</surname><given-names>D</given-names></name><name><surname>Breitner</surname><given-names>J</given-names></name></person-group><article-title>Mental and behavioral disturbances in dementia: findings from the
Cache County Study on Memory in Aging</article-title><source>Am J Psychiatry</source><year>2000</year><volume>157</volume><issue>5</issue><fpage>708</fpage><lpage>714</lpage><pub-id pub-id-type="pmid">10784462</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lyketsos</surname><given-names>CG</given-names></name><name><surname>Carrillo</surname><given-names>MC</given-names></name><name><surname>Ryan</surname><given-names>JM</given-names></name><name><surname>Khachaturian</surname><given-names>AS</given-names></name><name><surname>Trzepacz</surname><given-names>P</given-names></name><name><surname>Amatniek</surname></name><etal/></person-group><article-title>Neuropsychiatric symptoms in Alzheimer's disease</article-title><source>Alzheimers Dement</source><year>2011</year><volume>7</volume><issue>5</issue><fpage>532</fpage><lpage>539</lpage><pub-id pub-id-type="pmid">21889116</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schreinzer</surname><given-names>D</given-names></name><name><surname>Ballaban</surname><given-names>T</given-names></name><name><surname>Brannath</surname><given-names>W</given-names></name><name><surname>Lang</surname><given-names>T</given-names></name><name><surname>Hilger</surname><given-names>E</given-names></name><name><surname>Fasching</surname><given-names>P</given-names></name><etal/></person-group><article-title>Components of behavioral pathology in dementia</article-title><source>Int J Geriatr Psychiatry</source><year>2005</year><volume>20</volume><issue>2</issue><fpage>137</fpage><lpage>145</lpage><pub-id pub-id-type="pmid">15660411</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okura</surname><given-names>T</given-names></name><name><surname>Plassman</surname><given-names>B</given-names></name><name><surname>Steffens</surname><given-names>D</given-names></name><name><surname>Llewellyn</surname><given-names>DJ</given-names></name><name><surname>Potter</surname><given-names>GG</given-names></name><name><surname>Langa</surname><given-names>KM</given-names></name></person-group><article-title>Prevalence of Neuropsychiatric Symptoms and their association
with functional limitations in older adults in the United States: the aging,
demographics and memory study</article-title><source>J Am Geriatr Soc</source><year>2010</year><volume>58</volume><issue>2</issue><fpage>330</fpage><lpage>337</lpage><pub-id pub-id-type="pmid">20374406</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steinberg</surname><given-names>M</given-names></name><name><surname>Shao</surname><given-names>H</given-names></name><name><surname>Zandi</surname><given-names>P</given-names></name><name><surname>Lyketsos</surname><given-names>CG</given-names></name><name><surname>Welsh-Bohmer</surname><given-names>KA</given-names></name><name><surname>Norton</surname><given-names>MC</given-names></name><etal/></person-group><article-title>Point and 5-year period prevalence of neuropsychiatric symptoms
in dementia: the Cache County Study</article-title><source>Int J GeriatrPsychiatry</source><year>2008</year><volume>23</volume><issue>2</issue><fpage>170</fpage><lpage>177</lpage></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ford</surname><given-names>A</given-names></name></person-group><article-title>Neuropsychiatric aspects of dementia</article-title><source>Maturitas</source><year>2014</year><volume>79</volume><fpage>209</fpage><lpage>215</lpage><pub-id pub-id-type="pmid">24794580</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cerejeira</surname><given-names>J</given-names></name><name><surname>Lagarto</surname><given-names>L</given-names></name><name><surname>Mukaetova-Ladinska</surname><given-names>EB</given-names></name></person-group><article-title>Behavioral and Psychological Symptoms of Dementia</article-title><source>Frontiers in Neurology</source><year>2012</year><volume>3</volume><fpage>73</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.3389/fneur.2012.00073</pub-id><pub-id pub-id-type="pmid">22586419</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slachevsky</surname><given-names>A</given-names></name><name><surname>Budinich</surname><given-names>M</given-names></name><name><surname>Miranda-Castillo</surname><given-names>C</given-names></name><name><surname>N&#x000fa;&#x000f1;ez-Huasaf</surname><given-names>J</given-names></name><name><surname>Silva</surname><given-names>JR</given-names></name><name><surname>Mu&#x000f1;oz-Neira</surname><given-names>C</given-names></name><etal/></person-group><article-title>The CUIDEME study: determinants of burden in Chilean primary
caregivers of patients with dementia</article-title><source>J Alzheimers Dis</source><year>2013</year><volume>35</volume><fpage>297</fpage><lpage>306</lpage><pub-id pub-id-type="pmid">23422358</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cummings</surname><given-names>JL</given-names></name><name><surname>Mega</surname><given-names>M</given-names></name><name><surname>Gray</surname><given-names>K</given-names></name><name><surname>Rosenberg-Thompson</surname><given-names>S</given-names></name><name><surname>Carusi</surname><given-names>DA</given-names></name><name><surname>Gornbein</surname><given-names>J</given-names></name></person-group><article-title>The Neuropsychiatric Inventory: comprehensive assessment of
psychopathology in dementia</article-title><source>Neurology</source><year>1994</year><volume>44</volume><fpage>2308</fpage><lpage>2314</lpage><pub-id pub-id-type="pmid">7991117</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaufer</surname><given-names>D</given-names></name><name><surname>Cummings</surname><given-names>J</given-names></name><name><surname>Ketchel</surname><given-names>P</given-names></name><name><surname>Smith</surname><given-names>V</given-names></name><name><surname>MacMillan</surname><given-names>A</given-names></name><name><surname>Shelley</surname><given-names>T</given-names></name><etal/></person-group><article-title>Validation of the NPI-Q, a brief clinical form of the
Neuropsychiatric Inventory</article-title><source>J Neuropsychiatry Clin Neurosci</source><year>2000</year><volume>12</volume><fpage>233</fpage><lpage>239</lpage><pub-id pub-id-type="pmid">11001602</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boada</surname><given-names>M</given-names></name><name><surname>Cejudo</surname><given-names>J</given-names></name><name><surname>T&#x000e1;rraga</surname><given-names>L</given-names></name><name><surname>L&#x000f3;pez</surname><given-names>L</given-names></name><name><surname>Kaufer</surname><given-names>D</given-names></name></person-group><article-title>Neuropsychiatric Inventory Questionnaire (NPI-Q):
validaci&#x000f3;n espa&#x000f1;ola de una forma abreviada del
Neuropsychiatric Inventory (NPI)</article-title><source>Neurology</source><year>2002</year><volume>17</volume><fpage>317</fpage><lpage>323</lpage></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camozzato</surname><given-names>A</given-names></name><name><surname>Godinho</surname><given-names>C</given-names></name><name><surname>Kochhann</surname><given-names>R</given-names></name><name><surname>Massochini</surname><given-names>G</given-names></name><name><surname>Chaves</surname><given-names>M</given-names></name></person-group><article-title>Validity of the Brazilian version of the Neuropsychiatric
Inventory Questionnaire (NPI-Q)</article-title><source>Arq Neuropsiquiatr</source><year>2015</year><volume>73</volume><issue>1</issue><fpage>41</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">25608126</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perez-Zepeda</surname><given-names>MU</given-names></name><name><surname>Reyes-Guerrero</surname><given-names>J</given-names></name><name><surname>Rosas-Carasco</surname><given-names>O</given-names></name><name><surname>Gutierrez-Robledo</surname><given-names>LM</given-names></name></person-group><article-title>Validation of the neuropsychiatric inventory questionnaire in a
group of Mexican patients with dementia</article-title><source>Alzheimers Dement</source><year>2008</year><volume>4</volume><issue>4</issue><fpage>527</fpage><lpage>528</lpage></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hughes</surname><given-names>CP</given-names></name><name><surname>Berg</surname><given-names>L</given-names></name><name><surname>Danziger</surname><given-names>WL</given-names></name><name><surname>Coben</surname><given-names>LA</given-names></name><name><surname>Martin</surname><given-names>RL</given-names></name></person-group><article-title>A new clinical scale for the staging of dementia</article-title><source>Br J Psychiatry</source><year>1982</year><volume>140</volume><fpage>566</fpage><lpage>572</lpage><pub-id pub-id-type="pmid">7104545</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKhann</surname><given-names>G</given-names></name><name><surname>Drachman</surname><given-names>D</given-names></name><name><surname>Folstein</surname><given-names>M</given-names></name><name><surname>Katzman</surname><given-names>R</given-names></name><name><surname>Price</surname><given-names>D</given-names></name><name><surname>Stadlan</surname><given-names>EM</given-names></name></person-group><article-title>Clinical diagnosis of Alzheimer's disease: report of the
NINCDS-ADRDA Work Group under the auspices of Department of Health and Human
Services task Force on Alzheimer's Disease</article-title><source>Neurology</source><year>1984</year><volume>34</volume><fpage>939</fpage><lpage>944</lpage><pub-id pub-id-type="pmid">6610841</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mu&#x000f1;oz-Neira</surname><given-names>C</given-names></name><name><surname>Henr&#x000ed;quez</surname><given-names>F</given-names></name><name><surname>Ihnen</surname><given-names>J</given-names></name><name><surname>Sanchez</surname><given-names>M</given-names></name><name><surname>Flores</surname><given-names>P</given-names></name><name><surname>Slachevsky</surname><given-names>A</given-names></name></person-group><article-title>Propiedades psicom&#x000e9;tricas y utilidad diagn&#x000f3;stica
del Addenbrooke's Cognitive Examination-Revised (ACE-R) en una muestra de
ancianos chilenos</article-title><source>Rev M&#x000e9;d Chile</source><year>2012</year><volume>140</volume><issue>8</issue><fpage>1006</fpage><lpage>1013</lpage><pub-id pub-id-type="pmid">23282773</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>SPSS</collab><collab>IBM</collab></person-group><year>2013</year><source>IBM SPSS statistics 22</source><publisher-loc>New York</publisher-loc><publisher-name>IBM Corp</publisher-name></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kochhann</surname><given-names>R</given-names></name><name><surname>Borba</surname><given-names>E</given-names></name><name><surname>Cerveira</surname><given-names>M</given-names></name><name><surname>Onyszko</surname><given-names>D</given-names></name><name><surname>de Jesus</surname><given-names>A</given-names></name><name><surname>Forster</surname><given-names>L</given-names></name><etal/></person-group><article-title>Neuropsychiatric symptoms as the main determinant of caregiver
burden in Alzheimer's disease</article-title><source>Dement Neuropsychol</source><year>2011</year><volume>5</volume><issue>3</issue><fpage>203</fpage><lpage>208</lpage></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qing-Fei</surname><given-names>Z</given-names></name><name><surname>Tan</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Jiang</surname><given-names>T</given-names></name><name><surname>Tan</surname><given-names>MS</given-names></name><name><surname>Tan</surname><given-names>L</given-names></name><etal/></person-group><article-title>The prevalence of neuropsychiatric symptoms in Alzheimer's
disease: Systematic review and meta-analysis</article-title><source>J Affect Disord</source><year>2016</year><volume>190</volume><fpage>264</fpage><lpage>271</lpage><pub-id pub-id-type="pmid">26540080</pub-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rohde</surname><given-names>G</given-names></name><name><surname>Quiroga</surname><given-names>P</given-names></name><name><surname>Fasce</surname><given-names>M</given-names></name><name><surname>Fasce</surname><given-names>F</given-names></name></person-group><article-title>Noncognitive symptoms in Alzheimer disease and caregivers
distress in Chile</article-title><source>Brain Cogn</source><year>2002</year><volume>49</volume><issue>2</issue><fpage>253</fpage><lpage>262</lpage><pub-id pub-id-type="pmid">15259404</pub-id></element-citation></ref><ref id="r25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brodaty</surname><given-names>H</given-names></name><name><surname>Connors</surname><given-names>M</given-names></name><name><surname>Ku</surname><given-names>J</given-names></name><name><surname>Woodward</surname><given-names>M</given-names></name><name><surname>Ames</surname><given-names>D</given-names></name></person-group><article-title>The course of neuropsychiatric symptoms in dementia: a 3-year
longitudinal study</article-title><source>J Am Med Direct Assoc</source><year>2015</year><volume>16</volume><issue>5</issue><fpage>380</fpage><lpage>387</lpage></element-citation></ref><ref id="r26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bergh</surname><given-names>S</given-names></name><name><surname>Selb&#x000e6;k</surname><given-names>G</given-names></name></person-group><article-title>The prevalence and the course of neuropsychiatric symptoms in
patients with dementia</article-title><source>Norsk Epidemiologi</source><year>2012</year><volume>22</volume><issue>2</issue><fpage>225</fpage><lpage>232</lpage></element-citation></ref><ref id="r27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaufer</surname><given-names>D</given-names></name><name><surname>Jeffrey</surname><given-names>L</given-names></name><name><surname>Cummings</surname><given-names>M</given-names></name><name><surname>Bray</surname><given-names>T</given-names></name><name><surname>Castellon</surname><given-names>S</given-names></name><name><surname>Masterman</surname><given-names>D</given-names></name><etal/></person-group><article-title>Assessing the Impact of Neuropsychiatric Symptoms in Alzheimer's
Disease: The Neuropsychiatric Inventory Caregiver Distress
Scale</article-title><source>J Am Geriatr Society</source><year>1998</year><volume>46</volume><issue>2</issue><fpage>210</fpage><lpage>215</lpage></element-citation></ref><ref id="r28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ling Tan</surname><given-names>L</given-names></name><name><surname>Bee Wong</surname><given-names>H</given-names></name><name><surname>Allen</surname><given-names>H</given-names></name></person-group><article-title>The impact of neuropsychiatric symptoms of dementia on distress
in family and professional caregivers in Singapore</article-title><source>Int Psychogeriatrics</source><year>2005</year><volume>17</volume><fpage>253</fpage><lpage>263</lpage></element-citation></ref><ref id="r29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>M</given-names></name><name><surname>Liao</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Lai</surname><given-names>T</given-names></name></person-group><article-title>Caregiver burden associated with behavioral and psychological
symptoms of dementia (BPSD) in Taiwanese elderly</article-title><source>Arch Gerontol Geriatrics</source><year>2012</year><volume>55</volume><issue>1</issue><fpage>55</fpage><lpage>59</lpage></element-citation></ref></ref-list></back></article>